SOBRE ESTE PODCAST 🔗

Apresentadores:
Frequência de atualização:
every 42 days
Duração média do áudio:
33 minutes
Entrevistas com convidados
Tem patrocinadores
Inglês
Estados Unidos da América
40 episódios
desde 12 de Outubro de 2021
episodic

ÚLTIMO EPISÓDIO 🔗

Lessons from Season 3

In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes…

PESQUISAR EPISÓDIOS PASSADOS

Pesquisar episódios anteriores de Invent: Life Sciences.

EPISÓDIOS ANTERIORES

In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients. Stuart speaks with leading experts about the evoluti…
Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to opera…
In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts as they discuss what must change for CGTs to deliver on their full potential.
In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only ju…
In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva, and Wenshu Xu, Drug Discovery Tools Team Lead at TTP, we review the progress …
In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industry faces mounting pressure to address its carbon emissions, deploy cutting-edge …
In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. W…
The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many pat…
Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this…
Aviso: O podcast e a arte incorporada nesta página são de TTP plc, que é propriedade de seu proprietário e não é afiliado ou endossado por Listen Notes, Inc.